MAGEC1

Summary

MAGEC1 (MAGE family member C1, HGNC:6812) is a protein-coding gene on chromosome Xq27.2, encoding Melanoma-associated antigen C1 (O60732).

This gene is a member of the melanoma antigen gene (MAGE) family. The proteins of this family are tumor-specific antigens that can be recognized by autologous cytolytic T lymphocytes. This protein contains a large number of unique short repetitive sequences in front of the MAGE-homologous sequence, and therefore is about 800 aa longer than the other MAGE proteins.

Source: NCBI Gene 9947 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 261 total
• Phenotypes (HPO): 1
• MANE Select transcript: NM_005462

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6812
Approved symbol	MAGEC1
Name	MAGE family member C1
Location	Xq27.2
Locus type	gene with protein product
Status	Approved
Aliases	MAGE-C1, CT7, MGC39366, CT7.1
Ensembl gene	ENSG00000155495
Ensembl biotype	protein_coding
OMIM	300223
Entrez	9947

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000285879, ENST00000406005

RefSeq mRNA: 1 — MANE Select: NM_005462 NM_005462

CCDS: CCDS35417

Canonical transcript exons

ENST00000285879 — 4 exons

Exon	Start	End
ENSE00001021124	141905409	141909374
ENSE00001452910	141904717	141904814
ENSE00001452911	141903894	141903978
ENSE00003459900	141904970	141905076

Expression profiles

Bgee: expression breadth broad, 22 present calls, max score 84.82.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.5325 / max 89.5641, expressed in 117 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
197888	1.2073	108
197889	0.3251	68

Top tissues by expression

254 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.82	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	79.40	gold quality
right testis	UBERON:0004534	74.00	gold quality
testis	UBERON:0000473	72.52	gold quality
left testis	UBERON:0004533	71.65	gold quality
endometrium epithelium	UBERON:0004811	56.73	gold quality
decidua	UBERON:0002450	56.55	gold quality
hair follicle	UBERON:0002073	52.43	gold quality
sural nerve	UBERON:0015488	51.12	gold quality
frontal pole	UBERON:0002795	50.41	gold quality
middle frontal gyrus	UBERON:0002702	50.30	gold quality
tibialis anterior	UBERON:0001385	50.28	silver quality
paraflocculus	UBERON:0005351	50.18	gold quality
Brodmann (1909) area 10	UBERON:0013541	50.18	gold quality
quadriceps femoris	UBERON:0001377	50.17	gold quality
cranial nerve II	UBERON:0000941	49.71	silver quality
deltoid	UBERON:0001476	49.64	gold quality
Brodmann (1909) area 46	UBERON:0006483	49.30	gold quality
blood vessel layer	UBERON:0004797	49.29	gold quality
cerebellar vermis	UBERON:0004720	49.25	gold quality
cervix squamous epithelium	UBERON:0006922	49.20	gold quality
vastus lateralis	UBERON:0001379	49.11	gold quality
oviduct epithelium	UBERON:0004804	48.97	gold quality
ileal mucosa	UBERON:0000331	48.95	silver quality
olfactory bulb	UBERON:0002264	48.92	gold quality
upper leg skin	UBERON:0004262	48.90	silver quality
choroid plexus epithelium	UBERON:0003911	48.89	gold quality
myocardium	UBERON:0002349	48.87	gold quality
type B pancreatic cell	CL:0000169	48.83	gold quality
thymus	UBERON:0002370	48.68	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.46

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

41 targeting MAGEC1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489
HSA-MIR-548O-5P	99.94	71.24	3488
HSA-MIR-548W	99.94	71.24	3488
HSA-MIR-548Y	99.94	71.28	3514
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248

Literature-anchored findings (GeneRIF, showing 23)

• MAGE-C1 is cancer-testis antigen suitable for immune targeting in multiple myeloma. (PMID:11872084)
• Overexpression of MAGE-C1 is associated with mammary gland and ovary, non small cell lung carcinoma and metastatic melanoma (PMID:12115486)
• Estimation of CT7, also referred to as MAGE-C1, immunoreactivity is of limited prognostic usefulness in breast cancer. (PMID:17607369)
• MAGEC1/CT7, MAGEA3/6 and LAGE-1 are good candidates for immunotherapy, since together they cover 85% of our MM cases. (PMID:18237105)
• MAGE-C1/CT7 plays an important role in promoting survival in multiple myeloma cells. (PMID:20015885)
• cancer-testis antigens particularly CT7, are immunogenic in multiple myeloma patients (PMID:20108890)
• a content of >/=50% MAGE-C1/CT7 expressing myeloma cells in a sample was associated with reduced overall survival (p=0.013). (PMID:20621094)
• Peripheral blood mononuclear cells from 26 metastatic melanoma patients expressing CT7 in their tumor lesions were analyzed for CT7-specific T-cell responses using overlapping peptides. (PMID:20696919)
• Results suggest that the expression of MAGE-C1/CT7 and MAGE-C2/CT10 in primary melanoma is a potent predictor of sentinel lymph node metastasis. (PMID:21738656)
• Data with miRNA target analysis showed that 12 of them had possible target sites in the MAGEC1 gene. (PMID:21810217)
• the role of MAGE-C1/CT7 in the control of cellular proliferation and cell cycle in myeloma (PMID:22110734)
• the present study confirmed MAGE-C1/CT7 and MAGE-C2/CT7 expression in monoclonal gammopathies (PMID:23180015)
• Expression of the novel CT antigen MAGE-C1/CT7 was most commonly seen with positivity in 24.5 % of primary and 35.1 % of recurrent ovarian carcinomas (PMID:23529156)
• Positive results of immunohistostaining were obtained in 16 (35.6%), 7 (15.6%) and 36 (80.0%) samples using MAGE-C1, NY-ESO-1 and Sp17 antibodies, respectively (PMID:23923079)
• MAGE-C1 and MAGE-C2 are expressed in myeloma, but the chromosome aberrations do not always correlate with expression (PMID:24820892)
• Study identified the YKL40 and MAGEC1 genes as temozolomide (TMZ) resistanceassociated biomarkers in the TMZR U87 cell line, which showed an obvious resistance in vivo. (PMID:24842123)
• MAGEC1/CT7 was expressed in 66% of MM samples. (PMID:24896625)
• MAGE C1 expression was observed consistently in the early stem cells (CD34+) and early pro-B to pre-B cells (CD34+/-/CD19+), as well as the proliferating plasma cells. (PMID:25793710)
• expression of CT7 and CT10 throughout the different subtypes of mucosal melanoma and tumor development. (PMID:26161400)
• MAGE-C1 and MAGE-C2 expressions were positively associated with high tumor grade and reduced recurrence-free survival in breast cancer. (PMID:26321295)
• Results suggest that melanoma antigen, family C, 1 protein (MAGE-C1/CT7) expression is associated with inferior outcome of patients with multiple myeloma (MM) from a Chinese population. (PMID:27248683)
• In patients with Colon cancer, the expression of MAGE-C1 gene was related to a favorable prognosis. (PMID:28631709)
• The Association of Melanoma-Associated Antigen-C Gene With Clinicopathological Characteristics and Prognosis in Breast Cancer: A Systematic Review and Meta-Analysis. (PMID:37872029)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ndnl2	ENSDARG00000058212
mus_musculus	Magea13	ENSMUSG00000046180
rattus_norvegicus	Magea13	ENSRNOG00000003532
drosophila_melanogaster	MAGE	FBGN0037481

Paralogs (37): MAGEC2 (ENSG00000046774), TRO (ENSG00000067445), MAGEB2 (ENSG00000099399), MAGED2 (ENSG00000102316), MAGEB4 (ENSG00000120289), MAGEA9 (ENSG00000123584), MAGEA10 (ENSG00000124260), MAGEA4 (ENSG00000147381), MAGED4 (ENSG00000154545), MAGEA8 (ENSG00000156009), MAGEC3 (ENSG00000165509), MAGEB6 (ENSG00000176746), MAGEB18 (ENSG00000176774), MAGEF1 (ENSG00000177383), MAGEB10 (ENSG00000177689), MAGED1 (ENSG00000179222), NDN (ENSG00000182636), MAGEB17 (ENSG00000182798), MAGEA2B (ENSG00000183305), NSMCE3 (ENSG00000185115), MAGEA11 (ENSG00000185247), MAGEE2 (ENSG00000186675), MAGED4B (ENSG00000187243), MAGEH1 (ENSG00000187601), MAGEB5 (ENSG00000188408), MAGEB16 (ENSG00000189023), MAGEA6 (ENSG00000197172), MAGEA1 (ENSG00000198681), MAGEB3 (ENSG00000198798), MAGEE1 (ENSG00000198934), MAGEA12 (ENSG00000213401), MAGEB1 (ENSG00000214107), MAGEA3 (ENSG00000221867), MAGEB6B (ENSG00000232030), MAGEL2 (ENSG00000254585), MAGEA9B (ENSG00000267978), MAGEA2 (ENSG00000268606)

Protein

Protein identifiers

Melanoma-associated antigen C1 — O60732 (reviewed: O60732)

Alternative names: Cancer/testis antigen 7.1, MAGE-C1 antigen

All UniProt accessions (1): O60732

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Cytoplasm.

Tissue specificity. Expressed in testis and in tumors of a wide variety of histologic types.

Isoforms (2)

UniProt ID	Names	Canonical?
O60732-1	1	yes
O60732-2	2

RefSeq proteins (1): NP_005453* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002190	MHD_dom	Domain
IPR037445	MAGE	Family
IPR041898	MAGE_WH1	Homologous_superfamily
IPR041899	MAGE_WH2	Homologous_superfamily

Pfam: PF01454

UniProt features (41 total): sequence conflict 15, compositionally biased region 9, sequence variant 6, modified residue 4, region of interest 4, chain 1, domain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O60732-F1	49.28	0.03

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 63, 207, 382, 1063

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 41 (showing top): MISSIAGLIA_REGULATED_BY_METHYLATION_UP, MODULE_379, HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP, MODULE_242, HAMAI_APOPTOSIS_VIA_TRAIL_DN, PARENT_MTOR_SIGNALING_UP, MODULE_104, ZHAN_MULTIPLE_MYELOMA_MS_DN, MODULE_7, MORF_MYL3, MODULE_181, MORF_ERCC4, chrXq27, GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II, MODULE_41

GO Biological Process (1): negative regulation of transcription by RNA polymerase II (GO:0000122)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): nucleus (GO:0005634), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

716 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MAGEC1	DSE	Q9UL01	828
MAGEC1	SART1	O43290	810
MAGEC1	CTAG1A	P78358	767
MAGEC1	XAGE1B	Q9HD64	726
MAGEC1	CTAG2	O75638	696
MAGEC1	SSX4	O60224	654
MAGEC1	CT45A1	Q5HYN5	649
MAGEC1	SAGE1	Q9NXZ1	625
MAGEC1	SSX1	Q16384	610
MAGEC1	CAGE1	Q8TC20	609
MAGEC1	LIPI	Q6XZB0	571
MAGEC1	SLC39A7	Q92504	547
MAGEC1	LUZP4	Q9P127	541
MAGEC1	ACRBP	Q8NEB7	540
MAGEC1	MAGEB6	Q8N7X4	525

IntAct

17 interactions, top by confidence:

A	B	Type	Score
MAGEC1	CTAG1A	psi-mi:“MI:0915”(physical association)	0.540
CTAG1A	MAGEC1	psi-mi:“MI:0915”(physical association)	0.540
MAGEC1	CTAG1A	psi-mi:“MI:0403”(colocalization)	0.540
SUV39H1	MAGEC1	psi-mi:“MI:0914”(association)	0.530
RUSC2	MAGEC1	psi-mi:“MI:0915”(physical association)	0.370
MAGEC1	GTF2F1	psi-mi:“MI:0915”(physical association)	0.370
ECHDC2	MAGEC1	psi-mi:“MI:0915”(physical association)	0.370
MAGEC1	ATP5MG	psi-mi:“MI:0915”(physical association)	0.370
MRPL19	MAGEC1	psi-mi:“MI:0915”(physical association)	0.370
MAGEC1	H2AZ1	psi-mi:“MI:0915”(physical association)	0.370
SOX2	DDX39A	psi-mi:“MI:0914”(association)	0.350
AGGF1	BLTP3B	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (21): MAGEC1 (Affinity Capture-MS), MAGEC1 (Affinity Capture-MS), MAGEC1 (Affinity Capture-MS), MAGEC1 (Affinity Capture-MS), MAGEC1 (Affinity Capture-MS), MAGEC1 (Proximity Label-MS), MAGEC1 (Affinity Capture-MS), MAGEC1 (Affinity Capture-MS), MAGEC1 (Affinity Capture-MS), MAGEC1 (Affinity Capture-MS), CTAG1B (Two-hybrid), GTF2F1 (Two-hybrid), H2AFZ (Two-hybrid), ROCK2 (Two-hybrid), ATP5L (Two-hybrid)

ESM2 similar proteins: A0A087WUL8, A0A0J9YWL9, A0A0U1RQI7, A6NJU9, A6NNC1, A6QL64, A7XUY5, A8MRT5, B2SU53, C9JG80, E5RHQ5, E9Q6E9, F8W0I5, O43345, O59779, O60732, P02895, P06916, P09815, P0DPF3, P13208, P13813, P14417, P20465, P20469, P21733, P32072, Q00130, Q13117, Q3BBV0, Q4ZJY7, Q4ZJZ0, Q4ZJZ1, Q4ZJZ3, Q5HY64, Q5JPF3, Q5SSG8, Q5TAG4, Q5TI25, Q63661

Diamond homologs: A0A0J9YX57, A1A5P9, A2A368, A2A9R3, A6NCF6, A6QLI5, A8MXT2, O15479, O15480, O15481, O60732, P25233, P43355, P43356, P43357, P43358, P43360, P43361, P43362, P43363, P43364, P43365, P43366, Q12816, Q4R998, Q5PPP4, Q5RFC2, Q6AY37, Q6ITT4, Q6PCZ4, Q8BQR7, Q8N7X4, Q8TD90, Q8TD91, Q96JG8, Q96LZ2, Q96M61, Q96MG7, Q99608, Q9BE18

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

261 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	194
Likely benign	41
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

611 predictions. Top by Δscore:

Variant	Effect	Δscore
X:141904812:AAGGT:A	donor_loss	1.0000
X:141904815:GTGA:G	donor_loss	1.0000
X:141904816:T:A	donor_loss	1.0000
X:141905303:G:GT	donor_gain	1.0000
X:141903975:CAAGG:C	donor_loss	0.9900
X:141903978:GGT:G	donor_loss	0.9900
X:141903979:G:C	donor_loss	0.9900
X:141904713:GCAG:G	acceptor_loss	0.9900
X:141904714:CAGGT:C	acceptor_loss	0.9900
X:141904715:A:AG	acceptor_gain	0.9900
X:141904715:AG:A	acceptor_gain	0.9900
X:141904716:G:GA	acceptor_gain	0.9900
X:141904716:GG:G	acceptor_gain	0.9900
X:141904716:GGT:G	acceptor_gain	0.9900
X:141904815:G:GG	donor_gain	0.9900
X:141905044:GCT:G	donor_gain	0.9900
X:141905294:G:GT	donor_gain	0.9900
X:141905300:G:GT	donor_gain	0.9900
X:141904715:AGGT:A	acceptor_gain	0.9800
X:141904716:GGTG:G	acceptor_gain	0.9800
X:141905042:GAGCT:G	donor_gain	0.9800
X:141905075:GG:G	donor_gain	0.9800
X:141905076:GG:G	donor_gain	0.9800
X:141905077:G:GG	donor_gain	0.9800
X:141905077:GT:G	donor_loss	0.9800
X:141905078:TGAGT:T	donor_loss	0.9800
X:141905079:G:GG	donor_loss	0.9800
X:141905719:G:T	donor_gain	0.9800
X:141904716:GGTGC:G	acceptor_gain	0.9700
X:141904967:CAGGT:C	acceptor_loss	0.9700

AlphaMissense

7579 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:141908610:T:C	F1069S	0.996
X:141908615:T:A	W1071R	0.994
X:141908615:T:C	W1071R	0.994
X:141908160:T:C	L919P	0.993
X:141908148:T:C	L915S	0.992
X:141908205:T:G	M934R	0.991
X:141908417:A:C	S1005R	0.991
X:141908419:T:A	S1005R	0.991
X:141908419:T:G	S1005R	0.991
X:141908261:G:C	A953P	0.990
X:141908609:T:C	F1069L	0.990
X:141908611:C:A	F1069L	0.990
X:141908611:C:G	F1069L	0.990
X:141908574:G:C	R1057P	0.988
X:141908205:T:C	M934T	0.987
X:141908205:T:A	M934K	0.986
X:141908565:T:C	L1054P	0.986
X:141908617:G:C	W1071C	0.986
X:141908617:G:T	W1071C	0.986
X:141908647:G:C	K1081N	0.986
X:141908647:G:T	K1081N	0.986
X:141908663:T:C	F1087L	0.985
X:141908665:T:A	F1087L	0.985
X:141908665:T:G	F1087L	0.985
X:141908217:T:A	V938D	0.984
X:141908240:T:C	F946L	0.982
X:141908242:T:A	F946L	0.982
X:141908242:T:G	F946L	0.982
X:141908262:C:A	A953D	0.982
X:141908241:T:C	F946S	0.981

dbSNP variants (sampled 300 via entrez): RS1000480354 (X:141908113 G>A), RS1001973129 (X:141905592 C>G,T), RS1003682 (X:141903065 T>C), RS1003696313 (X:141904296 G>A), RS1004194234 (X:141903497 T>A), RS1004236684 (X:141904507 C>T), RS1004602779 (X:141905325 C>T), RS1005066801 (X:141904182 G>C,T), RS1005711597 (X:141903921 C>G,T), RS1006612561 (X:141902627 G>C), RS1006743301 (X:141904941 C>A), RS1007746116 (X:141908053 C>T), RS1008746953 (X:141909381 G>C), RS1009895931 (X:141905042 G>T), RS1010287713 (X:141909604 G>A)

Disease associations

OMIM: gene MIM:300223 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (1): autism (MONDO:0005260)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST009007_2	High-grade serous ovarian cancer	2.000000e-07
GCST012335_30	Hodgkin’s lymphoma	7.000000e-11

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:1001516	ovarian serous carcinoma

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

8 total (human), top 8 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases expression	2
TAK-243	increases sumoylation	1
CGP 52608	affects binding, increases reaction	1
Acetaminophen	decreases expression	1
Gemcitabine	increases expression	1
Etoposide	affects response to substance	1
Valproic Acid	decreases methylation	1
Sodium Selenite	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms